Biliary tract cancer
Conditions
Interventions
Gemcitabine, cisplatin plus nab-paclitaxel group:Gemcitabine, cisplatin plus nab-paclitaxel group
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder cancer diagnosed by imaging or pathology; (2) Locally advanced or distant-metastasizing biliary tract cancer; (3) PS score 0-1; (4) Aged 18 to 75 years; (5) Had not received anti-tumor treatment before; (6) Normally function of main organs; (7) Voluntary participation.
Exclusion criteria
Exclusion criteria: (1) Concomitant with other tumors; (2) The presence of autoimmune diseases, or the presence of comorbidities requiring long-term use of hormones; (3) The presence of peripheral neuropathy assessed as grade 2 or greater by the National Cancer Institute's Common terminology for adverse events version 4.0; (4) Central nervous system diseases excluding brain metastases; (5) Difficulty in long-term follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median progression-free survival;Median overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;Progression-free survival and overall survival rate of 6 and 12 months;Duration of response;Adverse event rate; | — |
Countries
China
Contacts
Public ContactZhu Qing
West China Hospital, Sichuan University
Outcome results
None listed